According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Medications sold under brand names like Ozempic, Wegovy, and Saxenda have become famous for their weight-loss benefits, but ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.